Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia
Sponsor: Bejing Institute for Stem Cell and Regenerative Medicine
Listed as NCT05519384, this EARLY_PHASE1 trial focuses on Acute Myeloid Leukemia, Childhood and Refractory Leukemia and remains ongoing. Sponsored by Bejing Institute for Stem Cell and Regenerative Medicine, it has been updated 6 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Feb 2026 — Present [monthly]
Unknown EARLY_PHASE1
Status: Recruiting → Unknown
-
Sep 2024 — Feb 2026 [monthly]
Recruiting EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting EARLY_PHASE1
-
Oct 2023 — Jul 2024 [monthly]
Recruiting EARLY_PHASE1
-
Dec 2022 — Oct 2023 [monthly]
Recruiting EARLY_PHASE1
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Sep 2022 — Dec 2022 [monthly]
Not Yet Recruiting EARLY_PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bejing Institute for Stem Cell and Regenerative Medicine
- Institute for Stem cell and Regeneration, Chinese Academy of Sciences
- Institute of Hematology & Blood Diseases Hospital, China
For direct contact, visit the study record on ClinicalTrials.gov .